(1S,3R,6S,8R,11S,13R,16S,18R,21S,23R,26S,28R,31S,33R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1S,3R,6S,8R,11S,13R,16S,18R,21S,23R,26S,28R,31S,33R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol
• 化学式: C₄₂H₇₀O₃₅
• 分子量: 1135.0
• InChiKey: WHGYBXFWUBPSRW-IWMWYTGBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -15
• 重原子数：
  77
• 可旋转键数：
  7
• 环数：
  21.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  554
• 氢给体数：
  21
• 氢受体数：
  35

文献信息

• COMPOSITIONS CONTAINING INCLUSION COMPLEXES
  申请人：Pun Suzie Hwang

  公开号：US20110182864A1

  公开（公告）日：2011-07-28

  The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:

  本发明提供一种含有聚合物和治疗剂的颗粒复合物的组合物。该组合物还包含一个络合剂。聚合物与络合剂通过主客或客主相互作用形成包含物复合物。本发明的治疗组合物可用于输送治疗剂并治疗各种疾病。颗粒复合物的聚合物和络合剂均可用于向治疗组合物引入功能。本发明还涉及一种制备组合物的方法。该方法将治疗剂、具有主客或客主功能的聚合物和具有客或主功能的络合剂结合起来形成治疗组合物。络合剂与聚合物形成包含物复合物。本发明还涉及一种输送治疗剂的方法。根据该方法，在需要治疗的哺乳动物（例如人或动物）中，向其注射本发明的治疗组合物的治疗有效量。还公开了具有以下公式的化合物：
• Compositions Useful for Reducing Toxicity Associated with Gadolinium-based Contrast Agents
  申请人：Rowe Vernon D.

  公开号：US20090155181A1

  公开（公告）日：2009-06-18

  The invention relates to compositions comprising a gadolinium-based contrast agent and a derivatized cyclodextrin. Further provided are methods for reducing the toxicity associated with gadolinium-based contrast agents.
• Methods for Reducing Cisplatin Nephrotoxicity
  申请人：Rowe Vernon D.

  公开号：US20110027390A1

  公开（公告）日：2011-02-03

  The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs such as cisplatin. The invention provides compositions comprising a substituted cyclodextrin, cisplatin and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the cisplatin.
• Methods of Reducing Methotrexate Nephrotoxicity
  申请人：Rowe Vernon D.

  公开号：US20110028413A1

  公开（公告）日：2011-02-03

  The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs such as methotrexate. The invention provides compositions comprising a substituted cyclodextrin, methotrexate and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the methotrexate.
• Compositions Useful for Reducing Nephrotoxicity and Methods of Use Thereof
  申请人：Rowe Vernon D.

  公开号：US20120321564A1

  公开（公告）日：2012-12-20

  The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted cyclodextrin, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.